The inhibition of antigen-induced bronchospasm by lodoxamide ethyl, a new drug with properties similar to those of cromolyn sodium, was studied in 13 asthmatic patients. Single doses were administered orally at weekly intervals in a double-blind randomized fashion 30 minutes before an inhalation challenge of antigen. The drug provided significant protection to immediate antigen-induced bronchospasm compared with placebo as measured by the antigen dose necessary to produce a drop of 20% or greater in the forced expiratory volume in 1 s.
Case RL, Rogers PB, VanArsdel PP, Altman LC. The Protective Effect of Lodoxamide on Antigen-Induced Bronchospasm: An Orally Active Antiallergic Drug. JAMA. 1982;247(5):661–664. doi:10.1001/jama.1982.03320300065028
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: